Source: GlobalNewswire

Press Release: Esperion : Esperion Partners with CSL Seqirus to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Australia

- Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales - - Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales -

Read full article »
Annual Revenue
$100-500M
Employees
250-500
Sheldon Koenig's photo - President & CEO of Esperion

President & CEO

Sheldon Koenig

CEO Approval Rating

83/100

Read more